NASDAQ : SPTX
Seaport Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 21.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.13B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 59.04M | 20.98M | 27.35M |
| Research & Development | 89.96M | 64.42M | 25.07M |
| Operating Expenses | 149.00M | 85.40M | 52.42M |
| Operating Income | -149.00M | -85.40M | -52.42M |
| Interest & Investment Income | 11.40M | 11.40M | 5.54M |
| Other Non Operating Income (Expenses) | -2.96M | -3.54M | |
| EBT Excluding Unusual Items | -140.56M | -77.54M | -46.88M |
| Gain (Loss) on Sale of Investments | 3.43M | 3.43M | |
| Pretax Income | -137.13M | -74.11M | -46.88M |
| Income Tax Expense | 1.41M | 773.00K | |
| Net Income | -138.54M | -74.88M | -46.88M |
| Net Income to Common | -138.54M | -74.88M | -46.88M |
| Shares Outstanding (Basic) | 28.72M | 7.46M | 2.96M |
| Shares Outstanding (Diluted) | 28.72M | 7.46M | 2.96M |
| EPS (Basic) | -4.82 | -10.04 | -15.83 |
| EPS (Diluted) | -4.82 | -10.04 | -15.83 |
| Free Cash Flow | -78.30M | -29.74M | |
| Free Cash Flow Per Share | -10.50 | -10.04 | |
| EBITDA | -148.87M | -85.22M | -52.25M |
| D&A For EBITDA | 128.00K | 173.00K | 166.00K |
| EBIT | -149.00M | -85.40M | -52.42M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 46.04M | 309.10M | |
| Short-Term Investments | 169.94M | ||
| Cash & Short-Term Investments | 273.31M | 215.98M | 309.10M |
| Other Receivables | 3.03M | ||
| Receivables | 3.03M | ||
| Prepaid Expenses | 1.18M | 393.00K | |
| Other Current Assets | 3.04M | 660.00K | |
| Total Current Assets | 223.23M | 310.15M | |
| Property, Plant & Equipment | 5.22M | 5.17M | |
| Long-Term Investments | 17.67M | ||
| Long-Term Deferred Charges | 1.20M | ||
| Other Long-Term Assets | 1.68M | 454.00K | |
| Total Assets | 249.01M | 315.78M | |
| Accounts Payable | 2.01M | 4.73M | |
| Accrued Expenses | 9.13M | 5.21M | |
| Current Portion of Leases | 1.64M | 857.00K | |
| Other Current Liabilities | 7.00K | 351.00K | |
| Total Current Liabilities | 12.78M | 11.15M | |
| Long-Term Leases | 3.44M | 4.15M | |
| Total Liabilities | 16.23M | 15.30M | |
| Common Stock | 1.00K | 1.00K | |
| Additional Paid-In Capital | 21.26M | 14.38M | |
| Retained Earnings | -114.11M | -39.23M | |
| Comprehensive Income & Other | 301.00K | ||
| Total Common Equity | 422.60M | -92.55M | -24.85M |
| Shareholders' Equity | 422.60M | 232.78M | 300.48M |
| Total Liabilities & Equity | 249.01M | 315.78M | |
| Total Debt | 5.02M | 5.08M | 5.01M |
| Net Cash (Debt) | 268.29M | 210.90M | 304.09M |
| Net Cash Per Share | 9.34 | 28.29 | 102.68 |
| Filing Date Shares Outstanding | 53.53M | 8.15M | 8.15M |
| Total Common Shares Outstanding | 53.53M | 8.15M | 8.15M |
| Working Capital | 210.45M | 299.00M | |
| Book Value Per Share | 7.89 | -11.35 | -3.05 |
| Tangible Book Value | 422.60M | -92.55M | -24.85M |
| Tangible Book Value Per Share | 7.89 | -11.35 | -3.05 |
| Machinery | 969.00K | 976.00K | |
| Leasehold Improvements | 432.00K | 101.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -74.88M | -46.88M | |
| Depreciation & Amortization | 1.41M | 214.00K | |
| Loss (Gain) From Sale of Assets | 11.00K | ||
| Loss (Gain) From Sale of Investments | -3.43M | ||
| Stock-Based Compensation | 6.88M | 14.52M | |
| Change in Accounts Payable | -2.73M | 1.72M | |
| Change in Other Net Operating Assets | -5.20M | 789.00K | |
| Operating Cash Flow | -77.94M | -29.63M | |
| Capital Expenditures | -356.00K | -113.00K | |
| Investment in Securities | -183.89M | ||
| Investing Cash Flow | -184.25M | -113.00K | |
| Issuance of Common Stock | 1.00K | ||
| Other Financing Activities | -874.00K | 13.20M | |
| Financing Cash Flow | -873.00K | 339.30M | |
| Foreign Exchange Rate Adjustments | 3.00K | ||
| Net Cash Flow | -263.06M | 309.55M | |
| Free Cash Flow | -78.30M | -29.74M | |
| Free Cash Flow Per Share | -10.50 | -10.04 | |
| Levered Free Cash Flow | -50.78M | ||
| Unlevered Free Cash Flow | -50.78M | ||
| Cash Income Tax Paid | 258.00K | ||
| Change in Working Capital | -7.93M | 2.51M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.07B | ||
| Enterprise Value | 802.85M | ||
| Debt / Equity Ratio | 0.01 | 0.02 | 0.02 |
| Net Debt / Equity Ratio | -0.64 | -0.91 | -1.01 |
| Net Debt / EBITDA Ratio | 1.80 | 2.48 | 5.82 |
| Net Debt / FCF Ratio | 2.69 | 10.22 | |
| Quick Ratio | 17.13 | 27.72 | |
| Current Ratio | 17.46 | 27.82 | |
| Return on Equity (ROE) | -28.08% | ||
| Return on Assets (ROA) | -18.90% | ||
| Return on Capital Employed (ROCE) | -36.10% | -17.20% | |
| Buyback Yield / Dilution | -1,101.91% | -151.76% |